In hepatobiliary and pancreatic diseases, for nonalcoholic fatty liver disease, Li et al. (52) found that vascular endothelial growth factor B (VEGFB) has the potential to regulate lipid metabolism and plays a regulatory role in the development and progression of NAFLD. Here, VEGFB is linked to metabolic dysfunction-associated steatotic liver disease.